Patents Assigned to Universite de Lausanne
-
Patent number: 8318898Abstract: The present invention describes materials and methods related to synthetic peptides which block the secretion of neurotransmitters and induce muscle relaxation, and use of said peptides as inhibitors of neurotransmitter secretion and muscle contraction, and as inducers of muscle relaxation.Type: GrantFiled: December 22, 2006Date of Patent: November 27, 2012Assignee: Universite de LausanneInventors: Nicolas Fasel, Amal Kūndig
-
Publication number: 20120192296Abstract: The present invention concerns the preparation of substantially purified agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof. The invention further relates to isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof as well as their use in the treatment of X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. The invention also relates to a pharmaceutical composition comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof and to a method of treating X-linked hypohidrotic ectodermal dysplasia and tooth agenesis. Finally, the present invention concerns a pharmaceutical kit comprising said isolated agonist anti-EDAR monoclonal antibodies or isolated monoclonal antibody fragments or antigen binding portions or fragments thereof.Type: ApplicationFiled: March 30, 2010Publication date: July 26, 2012Applicants: Universite de Lausanne, Edimer Biotech S.A.Inventors: Pascal Schneider, Nathalie Dunkel, Stephane Demotz
-
Patent number: 8110544Abstract: The present invention relates to a peptide consisting in the N2 sequence of the RasGAP protein, a fragment thereof, or a variant thereof which enhances the ability of a drug to selectively kill cells. Furthermore, it relates to a pharmaceutical composition comprising as an active substance a pharmaceutically effective amount of the peptide.Type: GrantFiled: June 30, 2004Date of Patent: February 7, 2012Assignee: Universite de LausanneInventors: Christian Widmann, Jiang-Yang Yang, David Michod
-
Publication number: 20120022000Abstract: The present invention relates to a peptide useful for the preparation of a medicament for the treatment or prevention of metastasis. Furthermore, it relates to a method of treatment or prevention of metastasis comprising administering to a subject in need thereof, a therapeutically effective amount of the peptide of the invention.Type: ApplicationFiled: January 29, 2010Publication date: January 26, 2012Applicant: UNIVERSITE DE LAUSANNEInventor: Christian Widmann
-
Publication number: 20110294873Abstract: The present invention relates to gene transfer vectors and in particular expression vectors which comprise at least one isolated DNA molecule having insulator and or boundary properties which limits the effects of a regulatory sequence upon another regulatory or coding sequence disposed upon the other side of said at least one isolated DNA molecule. The present invention also relates to methods of identifying isolated DNA molecule having insulator and or boundary properties and to the use of expression vector, in particular a retrovirus vector, in in vivo and ex vivo gene therapy methods as well as to cells and organisms transformed using vectors according to the present invention.Type: ApplicationFiled: October 23, 2009Publication date: December 1, 2011Applicant: UNIVERSITÉ DE LAUSANNEInventors: Nicolas Mermod, Armelle Gaussin, Germain Esnault
-
Publication number: 20110206257Abstract: This invention concerns an efficient algorithm for automatic and accurate segmentation of Abdominal Aortic Aneurysm (AAA). The algorithm first identifies the location of the lumen (the inner portion of aorta) and then segments it. The abdominal portion of the lumen is then found using anatomical and geometrical features. This portion of the lumen is straightened using geometrical transformation based on the smoothed centreline. The transformed lumen is then passed through a number of filters, based on geometrical, intensity, gradient and texture features, to search for the existence of the aneurysm. If aneurysm is detected, a deformable model is first initialized to the approximate borders of the aneurysm which are then refined using global and location information.Type: ApplicationFiled: April 16, 2009Publication date: August 25, 2011Applicant: UNIVERSITE DE LAUSANNEInventors: Salah Qanadli, Jamshid Dehmeshki, Hamdan Amin
-
Publication number: 20110110979Abstract: The present invention relates to a method for treating an infection or disease or lesion, in particular an HPV infection. Furthermore, it relates to a vaccine for treating a Human Papillomavirus (HPV) infection or an associated disease or lesion in a subject.Type: ApplicationFiled: April 1, 2009Publication date: May 12, 2011Applicant: Universite De LausanneInventor: Denise Nardelli Haefliger
-
Publication number: 20110076283Abstract: The present invention relates to a method for predicting or diagnosing outcome of concomitant chemo-radiotherapy of a subject suffering from brain tumor. The present invention further relates to compositions and methods for treatment or prevention of tumor resistance in a subject suffering from a brain tumor and to a kit useful for predicting or diagnosing the tumor resistance in a subject treated with concomitant chemo-radiotherapy.Type: ApplicationFiled: January 23, 2009Publication date: March 31, 2011Applicant: Universite De LausanneInventors: Monika Hegi, Anastasia Murat, Eugenia Migliavacca, Roger Stupp
-
Publication number: 20100318182Abstract: The sheath (1) for introducing devices such as a stent or other devices, said sheath comprising several reference markers (3) along a predetermined part of said sheath (1) for in situ measuring purposes.Type: ApplicationFiled: June 17, 2010Publication date: December 16, 2010Applicant: Universite de LausanneInventor: Salah Qanadli
-
Patent number: 7580737Abstract: A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second dvalue. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.Type: GrantFiled: February 21, 2002Date of Patent: August 25, 2009Assignee: Universite de LausanneInventors: Max Wintermark, Jean-Philippe Thiran, Reto Antoine Meuli
-
Patent number: 7033597Abstract: The invention relates to sequences of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.Type: GrantFiled: June 7, 2002Date of Patent: April 25, 2006Assignee: Université de LausanneInventor: Christophe Bonny
-
Patent number: 6960648Abstract: The invention relates to a sequence of amino acids with the capacity to facilitate transport of an effector across a biological membrane. More specifically, the present invention relates to novel peptide transporters that specifically target certain cell types for the intracellular delivery of drugs and therapeutic agents.Type: GrantFiled: October 15, 2001Date of Patent: November 1, 2005Assignee: Universite de LausanneInventor: Christophe Bonny
-
Patent number: 6943924Abstract: The present invention is related to a method for performing digital holographic imaging (DHI), said DHI being characterized by the fact that images of a sample are obtained by applying numerical means to reconstruct holograms of the sample. In the method of the invention, the sample is in a medium with controlled properties that influence the behaviour of the sample, and/or that influence the process of hologram formation. The information content of one hologram, or of a plurality of holograms, recorded with the sample in one medium, or in a plurality of medium, is used to reconstruct one image of the sample, or a plurality of images of the sample, that describe quantitatively one property of the sample, or a plurality of properties of the sample. The present invention is also related to an apparatus with which to perform said method.Type: GrantFiled: December 4, 2002Date of Patent: September 13, 2005Assignees: Ecole Polytechnique Federale de Lausanne (EPFL), Universite de Lausanne /BRAInventors: Pierre Marquet, Etienne Cuche, Christian Depeursinge, Pierre Magistretti
-
Patent number: 6792302Abstract: A method and apparatus for evaluating acute stroke patients and for determining whether a stroke patient will benefit from the use of thrombolysis therapy includes obtaining measurements of the cerebral blood flow and cerebral blood volume of the brain of a stroke patient, determining ischemic areas of the brain where the ischemic areas comprise the measurements of cerebral blood flow which are less than a first value and creating a penumbra-infarct map of the ischemic areas of the brain using the measurements. The infarct area corresponds to the area of the brain where cerebral blood volume is less than a second value. The penumbra area corresponds to the area of the brain where cerebral blood volume is greater than this second value. The method also includes determining a ratio of penumbra size to the total of penumbra size and infarct size. When the ratio is greater than a predetermined value, the stroke patient is a candidate for thrombolysis therapy.Type: GrantFiled: September 4, 2001Date of Patent: September 14, 2004Assignee: Universite de LausanneInventors: Max Wintermark, Jean-Philippe Thiran, Refo Antoine Meuli
-
Patent number: 6074875Abstract: This application relates to cell lines transfected with (a) nucleic acid encoding one or more hormone receptors, the receptors being capable of transmitting a signal, and (b) nucleic acid encoding a desired polypeptide, the nucleic acid encoding the polypeptide being under the control of a promoter containing regulatory elements responsive to the signal transmitted by the receptor(s) so that transcription of the nucleic acid encoding the desired polypeptide is modulated by the level of the hormone(s) in the patient. Preferably, the receptors are the GIP or GLP-1 receptors controlling the production of insulin in the cells in response to changes in the metabolic status of a patient. The application also relates to compositions comprising these cells and their use in methods of medical treatment.Type: GrantFiled: March 4, 1998Date of Patent: June 13, 2000Assignees: Ecole Polytechnique Federale de Lausanne, Universite de Lausanne, Centre Hospitalier Universitaire VaudoisInventor: Bernard Thorens